Stratipath

Molika Ashford from GenomeWeb and 360Dx recently interviewed our CEO, Fredrik Wetterhall, discussing how AI-based prognostic analyses are emerging as a viable alternative to genomic tests. And how this shift is already underway, with Stratipath Breast gaining traction in clinical settings and backed by growing scientific evidence. “The customers we have, they’re using our test as an alternative to molecular assays … and I think the main benefit with AI-based precision diagnostics is that they can get results in minutes instead of weeks,” says Fredrik Wetterhall in the interview. ”Although the company is still early in its clinical foray, Wetterhall said that it believes it can also serve markets where molecular testing has proliferated, including the UK and US, by offering a more rapid option.” https://lnkd.in/drtTCEB9

Swedish public radio recently reported that Unilabs Sverige and St. Göran’s Hospital are soon adopting Stratipath Breast for breast cancer risk profiling. We’re proud to collaborate and advance precision diagnostics at one of Sweden’s leading breast cancer clinics. Together, we’re making strides towards more accessible, rapid, and precise cancer care. #Stratipath #PrecisionMedicine #BreastCancer #AIDiagnostics #HealthcareInnovation #CancerCare

Today, our COO Annica Jämtén Ericsson and Medical Manager Stephanie Robertson proudly represented Stratipath at the Digital Pathology Algorithms (DP and AI) event hosted by Roche in Preston, UK. A big thank you to Luke Benko and Marta Canamero from Roche Diagnostics UK & Ireland for the engaging discussions and inspiring presentations. Your insights help drive innovation forward in digital pathology! Together, we are advancing AI-powered precision diagnostics to ensure that more patients receive the right treatment at the right time. #DigitalPathology #AI #PrecisionMedicine #HealthcareInnovation #BreastCancerDiagnostics

This morning, Stratipath co-founder Johan Hartman appeared as an expert guest on Swedish TV4’s morning news, alongside Susanne Dieroff Hay, Chair of Bröstcancerförbundet (the Swedish Breast Cancer Association). The discussion focused on the latest breast cancer report and the pressing issue of unequal access to precision diagnostics across the country. As advancements in diagnostics improve outcomes, addressing disparities in access remains a critical challenge in ensuring equal care for all patients. #BreastCancer #PrecisionDiagnostics #HealthcareEquality #AI https://lnkd.in/dvZxnk2c

In a recent interview with Impact Loop, Stratipath co-founder Johan Hartman shared exciting insights into Stratipath’s role in transforming cancer care: “We have the first product in this field approved for hospital use. But AI is advancing rapidly, so there will be competition, which is great. The market is large, so there’s room for more players.” Read the full article (in Swedish): https://lnkd.in/ghmuCK56

We had the pleasure of welcoming Brad Loncar from BiotechTV to Stockholm, where he caught up with our co-founder and Chief Medical Officer Johan Hartman. During their conversation, they delved into the pioneering innovation coming out of Karolinska Institutet, the journey of developing Stratipath, and how AI is reshaping cancer diagnostics.

ESMO 2024 kicks off today, and Stratipath will be there! Are you attending ESMO? This is a great opportunity to learn more about Stratipath's AI-driven solutions that are revolutionizing precision cancer diagnostics. Our cutting-edge tools are designed to enhance clinical decision-making, enable faster treatment pathways, and ensure more patients get the right care, cost-effectively. Interested in exploring potential collaborations, discussing clinical studies, or simply getting the latest updates on our work? Let’s connect! Our team is here and ready to meet: Annica Jämtén Ericsson - COO Johan Hartman - CMO, Co-founder (representing Karolinska Institutet, but available for meetings) Mattias Rantalainen - CTO, Co-founder (representing Karolinska Institutet, but available for meetings) Emelie Karlsson - Customer Service Specialist (representing Karolinska Institutet, but available for meetings) We look forward to seeing you at ESMO - European Society for Medical Oncology and discussing how we can drive better outcomes together!

Don’t miss out at ECP If you’re attending the European Congress of Pathology (ECP), make sure to catch the inspiring session by Stratipath co-founder, Professor Johan Hartman. He’ll be discussing “How AI will save us tomorrow: development of AI algorithms in pathology,” exploring how advanced AI technologies can revolutionize cancer diagnostics and patient care. Time: 15:20 CET, Location: Spadolini 4, Track: SPEC-08 | Joint Special Session ESP & National Societies: Is digital pathology going to save us?

This is a significant milestone in our mission to make precision diagnostics more accessible to patients, helping to improve outcomes for those affected by cancer. A huge thank you to the incredible team at Roche, especially Shikha O'Brien, PhD, Michael Rivers, and Petra de Verdier, and to the outstanding team at Stratipath, where Annica Jämtén Ericsson has been pivotal in driving this progress. Your dedication makes all the difference! #BreastCancer #PrecisionDiagnostics #PrecisionMedicine #ArtificialIntelligence #AI

Press release - Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics Stratipath, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform. Stratipath Breast is the first EU regulatory-compliant solution for risk stratification of breast cancer using AI-based precision diagnostics. This deep learning-based solution analyses digitised haematoxylin and eosin-stained histopathology images of breast cancer tissue to enable the identification of patients with increased risk of disease progression, thus providing novel decision support for clinicians in the diagnostic evaluation of breast cancer. In contrast to conventional molecular tests, AI-based risk profiling offers shorter turnaround times for results, delivers new insights at the point of diagnosis, and substantially reduces the reliance on expensive molecular testing. As a result, Stratipath Breast provides broader accessibility and benefits for a greater number of breast cancer patients. "Stratipath Breast represents a significant advancement by offering a faster and more cost-effective alternative to traditional molecular assays. By integrating with Roche’s navify® Digital Pathology enterprise software, a large number of pathology labs globally now gain rapid access to AI-based prognostic insights, all while streamlining laboratory processes and minimising costs." says Fredrik Wetterhall, CEO and co-founder of Stratipath. This collaboration between Stratipath and Roche represents a significant step forward in breast cancer diagnostics. By harnessing the power of artificial intelligence and digital pathology, the two organisations are committed to improving the lives of breast cancer patients worldwide. https://lnkd.in/dDtfMfhU